Neal Dixit, MD

UCSD AHFTC Fellow 2025-26 | UC Davis Cardiology '25 | UCLA Internal Medicine '22 | Tulane MD/MBA '19 | Believer in Heart Success |

[Neal Dixit, MD @NealDixit]

A 🧵on STRONG-HF 💪🏾🫀

⭐️The first randomized trial to show the immense benefits of a comprehensive high-intensity med-titration program with #HF GDMT

❓How did the investigators achieve an 8.1% ARR in HFH/mortality at 6 months❓

Let’s see what we can learn 👇🏾🧵

[Gregg Fonarow MD @gcfmd]

Won’t 💊 cost too much?

With generic pricing: $3.5 billion a year

Optimal implementation in eligible patients with HF, CKD & T2DM is projected to:

🏥 Reduce billions in CV/HF 🏨s

🫘 Avoid dialysis costs in CKD

Not prescribing SGLT2i way more costly

#SGLT2i #ValueBasedCare

[Neal Dixit, MD @NealDixit]

Excited to share our review on predicting sudden cardiac death in HFrEF led by outstanding med student Norayr Mkrtchyan!

It's a comprehensive look at the risk factors associated with sudden death in this population

@AntoinetteBirs @AHajduczok

https://t.co/HLgRVm0qub

[Neal Dixit, MD @NealDixit]

@ARKamathMD Come on Akshay this will certainly be an L! @drjohnm

[Circ: Heart Failure @CircHF]

Is finerenone ready for primetime in heart failure? We argue that the data suggest not yet. @NealDixit @cardiologyUc #AHAJournals https://t.co/V09flDbPmJ

[Neal Dixit, MD @NealDixit]

@DrJesseMorse @GymOClockk One of the most simple yet under appreciated concepts!

[Henry Han @HanCardiomd]

Is It Primetime for #Finerenone in #HeartFailure?

https://t.co/V9LqjCQL6w
@CircHF #MRA

[Neal Dixit, MD @NealDixit]

@jasonryanmd I used anki for echocardiography board review but 4 months out now I can’t say I retained much other than what I’m using for clinical practice.

[Neal Dixit, MD @NealDixit]

Is it primetime for finerenone in HF?

Would love to hear why or why not?

Here is our perspective 👇🏾

https://t.co/TE4lBtu3NS

[Alexander Hajduczok, MD 🇺🇦🙏 @AHajduczok]

Congrats @NealDixit !!! Can’t wait for you to join the awesome team at @UCSDCardiology ❤️

[Neal Dixit, MD @NealDixit]

Ecstatic to share that I will be joining @HowieTranMD and the team at @UCSDCardFellows for Advanced Heart Failure and Transplant Cardiology Fellowship!

[Gunnar Henrik Heine @gunnar_heine]

Is Finerenone just an expensive spironolactone?
"A RCT of nonsteroidal versus steroidal MRAs is desperately needed in the HF population"
Thanks for your thoughtful Editorial, @NealDixit and Saul Schaefer!
@dgfn_ev @YoungDgk @MarcusSaemann @hswapnil

https://t.co/uEgYU0prdD

[Neal Dixit, MD @NealDixit]

@shahad_Chalaby 🧐

[Steve Greene @SJGreene_md]

Costs? Intolerance? Inertia? Other? Primary reason for gaps in #GDMTworks endlessly debated.

🤔What if we had US physicians audit their own patient charts & report *WHY* they didn’t prescribe #GDMT for #HFrEF in each case?

🚨 Results in @JACCJournals

https://t.co/ho6Ah03KJy

[Neal Dixit, MD @NealDixit]

@AndrewJSauer HR is almost exactly the same as spironolactone in TOPCAT with Georgia/Russia excluded. Is there incremental benefit of finerenone over spiro/eplerenone? @gcfmd

[Neal Dixit, MD @NealDixit]

@ADiederichsen @drEdChau @DrMarthaGulati @ErinMichos @DrNathanWong @kewatson @hsbhatia @BudoffMd @rblument1 @DrMichaelShapir @gcfmd That's great, I hadn't seen that. Very clear mechanism of benefit of this screening measure!

[Neal Dixit, MD @NealDixit]

Will DANCAVAS be the most important screening trial in the last 50 years?

Interested to hear opinions!

Read our commentary 👇🏾

https://t.co/qD7cnjNYXV

[BiykemBozkurt @BiykemB]

Cost-Effectiveness of GDMT for HFmrEF & HFpEF
https://t.co/lKvkermbSH
@JACCJournals #JACCHF @gcfmd @boback @mvaduganathan @NealDixit @katieptr

[Jenny Thibodeau, MD, MSCS @JTThibs]

In #JACCHF @JACCJournals: cost effectiveness of medical tx for #HFmrEF & #HFpEF
*At current cost, MRA high value, SGLT2i intermediate value, & ARNI low value
*If generic, all are high value

🛑Need equitable access to meds for all!🛑

https://t.co/NAjiIxHRk7
@gcfmd @NealDixit

[Gregg Fonarow MD @gcfmd]

Generic priced options are here or just around the corner

Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction | JACC: Heart Failure https://t.co/pa5QuOGS6y

@NealDixit @JACCJournals

[Neal Dixit, MD @NealDixit]

@drscottyk I think misnomer that ASA has significantly lower bleed risk than DOAC. See from ARTESIA. Why take the bleed risk without at least getting all the ischemic protection?